Skip to Content
Merck
  • Lifestyle factors and efficacy of lifestyle interventions in gastroesophageal reflux disease patients with functional dyspepsia: primary care perspectives from the LEGEND study.

Lifestyle factors and efficacy of lifestyle interventions in gastroesophageal reflux disease patients with functional dyspepsia: primary care perspectives from the LEGEND study.

Internal medicine (Tokyo, Japan) (2015-04-04)
Ken Haruma, Yoshikazu Kinoshita, Shigeru Sakamoto, Katsuyuki Sanada, Shinzo Hiroi, Hiroto Miwa
ABSTRACT

Although gastroesophageal reflux disease (GERD), a very common disorder worldwide, is considered to be a lifestyle disease, the pathogenic role of lifestyle factors and consequently the efficacy of lifestyle interventions, remains controversial. Lifestyle factors associated with GERD and the beneficial effect of specific recommended lifestyle interventions in the primary care setting were evaluated as a post-hoc analysis of the LEGEND study which investigated the effect of lansoprazole in patients with GERD who reported dyspeptic symptoms. GERD patients with dyspepsia were treated with lansoprazole 15 mg or 30 mg daily for four weeks. Reflux and dyspeptic symptoms were evaluated using patient-reported questionnaires before and four weeks after the administration of lansoprazole. Among 12,653 patients, "feelings of continued stress" was the most common lifestyle factor (45.6% of patients), and >30% of the patients reported "eating sweet foods at least once every two to three days," "eating greasy foods at least once every two to three days" and "drinking coffee almost daily." Introducing lifestyle interventions had a significant effect on both reflux and dyspeptic symptoms. Lifestyle interventions are thus considered to be important in GERD patients with dyspepsia who receive a proton pump inhibitor.

MATERIALS
Product Number
Brand
Product Description

Lansoprazole, European Pharmacopoeia (EP) Reference Standard
USP
Lansoprazole, United States Pharmacopeia (USP) Reference Standard
Lansoprazole for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Lansoprazole, ≥98% (TLC), powder